Head-To-Head Comparison: Coherus Oncology (NASDAQ:CHRS) and CRISPR Therapeutics (NASDAQ:CRSP)

CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) and Coherus Oncology (NASDAQ:CHRS – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of current recommendations and price targets for CRISPR Therapeutics and Coherus Oncology, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics 1 6 8 2 2.65
Coherus Oncology 1 0 3 0 2.50

CRISPR Therapeutics presently has a consensus price target of $72.93, suggesting a potential upside of 80.65%. Coherus Oncology has a consensus price target of $11.00, suggesting a potential upside of 2,074.34%. Given Coherus Oncology’s higher possible upside, analysts plainly believe Coherus Oncology is more favorable than CRISPR Therapeutics.

Volatility and Risk

CRISPR Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Coherus Oncology has a beta of 1.03, suggesting that its share price is 3% more volatile than the S&P 500.

Institutional and Insider Ownership

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 72.8% of Coherus Oncology shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 7.2% of Coherus Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares CRISPR Therapeutics and Coherus Oncology’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics -1,812.07% -25.59% -17.89%
Coherus Oncology -253.43% -274.46% -69.87%

Earnings & Valuation

This table compares CRISPR Therapeutics and Coherus Oncology”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics $3.51 million 1,115.64 -$581.60 million ($4.74) -8.52
Coherus Oncology $42.17 million 1.85 $168.02 million ($0.97) -0.52

Coherus Oncology has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Coherus Oncology beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.

About CRISPR Therapeutics

(Get Free Report)

CRISPR Therapeutics AG is a biotechnology company focused on developing gene-based medicines using CRISPR/Cas9, a gene-editing technology that can make targeted changes to DNA. Founded in 2013, the company is headquartered in Zug, Switzerland, and maintains U.S. operations in Cambridge, Massachusetts. Its lead product, Casgevy (exa-cel), was developed with Vertex Pharmaceuticals for people with sickle cell disease and transfusion-dependent beta thalassemia. It was the first therapy based on CRISPR gene editing to receive regulatory approval.

About Coherus Oncology

(Get Free Report)

Coherus Oncology, formerly Coherus BioSciences, is a biopharmaceutical company focused on developing and commercializing cancer treatments. Its portfolio includes LOQTORZI (toripalimab-tpzi), an immune checkpoint inhibitor that targets PD-1 and is approved in the United States for certain patients with nasopharyngeal cancer. The company is also advancing a pipeline of investigational immuno-oncology medicines. Coherus historically built its business around biosimilar medicines before shifting its focus to oncology.

Receive News & Ratings for CRISPR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRISPR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.